Flunixin Injection

Flunixin Injection

Flunixin Injection is a widely used anti-inflammatory solution for injection containing 50mg/ml of flunixin. Indicated to indicated for the alleviate inflammation and pain associated with musculo-skeletal disorders and colic as well as the treatment of endotoxaemia or septic shock associated with gastric torsion in horses. It is indicated to treat acute inflammation associated respiratory disease in cattle and can be used as adjunctive therapy in the treatment of acute mastitis. It is also effective as an adjunctive therapy in treating swine respiratory disease. Legal Category POM

 





  • Active Ingredient

    Flunixin (as flunixin meglumine) 50 mg/ml

  • Pharmaceutical Form

    A sterile aqueous solution for injection.

  • Indications

    Flunixin Injection is indicated for use in cattle and horses in the alleviation of inflammation and pain. In the horse, Flunixin Injection is indicated for the alleviation of inflammatory signs associated with musculo-skeletal disorders and for the alleviation of visceral pain associated with colic. In cattle, Flunixin Injection is indicated for the control of acute inflammation associated with respiratory disease. Flunixin Injection has also been shown to have some benefit in the treatment of acute pulmonary emphysema [fog fever] and as adjunctive therapy in the treatment of acute mastitis. In pigs, Flunixin Injection is indicated as an adjunctive therapy in the treatment of swine respiratory diseases.

  • Dosage

    Flunixin Injection is indicated for intravenous administration to cattle and horses and intramuscular injection to pigs. Horses: For use in equine colic, the recommended dose rate is 1.1 mg flunixin/kg bodyweight equivalent to 1 ml per 45 kg bodyweight. Treatment may be repeated once or twice if colic recurs. During clinical trials, approximately 10% of the horses required one or two additional treatments. The cause of colic should be determined and treated with concurrent therapy. For use in musculo-skeletal disorders, the recommended dose rate is 1.1 mg flunixin/kg bodyweight equivalent to 1 ml per 45 kg bodyweight, once daily for up to 5 days according to clinical response.

    Cattle: For use in acute inflammatory conditions, the recommended dose rate is 2.2 mg flunixin/kg bodyweight equivalent to 2 ml per 45 kg bodyweight. Repeat as necessary at 24 hour intervals for up to 5 consecutive days.

    Pigs: For use in pigs, the recommended dose rate is 2.2 mg flunixin/kg bodyweight equivalent to 2 ml per 45 kg bodyweight once by intramuscular injection. Flunixin Injection should be administered as adjunctive therapy in conjunction with a suitable course of antibacterial therapy.

  • Contraindications

    Do not exceed the recommended dose or the duration of treatment. Do not administer to pregnant mares. Use is contraindicated in animals suffering from cardiac, hepatic or renal disease, where there is the possibility of gastro-intestinal ulceration or bleeding, where there is evidence of a blood dyscrasia or hypersensitivity to the product.

  • Special Warnings

    The cause of the underlying inflammatory condition or colic should be determined and treated with appropriate concomitant therapy.  [i] Special precautions for use in animals Avoid intra-arterial injection. Use in any animal less than 6 weeks of age or in aged animals may involve additional risk. If such use cannot be avoided animals may require a reduced dosage and careful clinical management. Avoid use in any dehydrated, hypovalaemic or hypotensive animal except in the case of endotoxaemia or septic shock. It is preferable that NSAIDs which inhibit prostaglandin synthesis are not administered to animals undergoing general anaesthesia until fully recovered.

    Special precautions to be taken by the person administering the veterinary medicinal product to animals: Flunixin meglumine is irritating to the eye. Avoid contact with the skin and splashes to the eye.

  • Adverse Reactions

    For this class of drug, untoward effects include gastrointestinal irritation, ulceration and, in dehydrated or hypovolaemic animals, potential for renal damage. There are occasional reports of collapse following rapid intravenous injection in horses and calves.

  • Withdrawal Period

    Meat: Animals must not be slaughtered for human consumption during treatment. Horses and cattle intended for human consumption may be slaughtered 7 days following treatment. Pigs intended for human consumption may be slaughtered 24 days following treatment. Milk for human consumption must not be taken during treatment. Milk: 36 hours. Milk intended for human consumption may only be taken from treated cows after 36 hours from the last treatment.

  • Packaging Size

    Flunixin Injection is supplied in 50ml and 100ml type I clear glass vials, complete with bromobutyl bungs and aluminium caps.

  • Shelf Life

    3 years.

    Following withdrawal of the first dose the product should be used within 28 days.

  • Marketing Authorisation

    VPA 1999/069/001

Please note: Product information presented on this website is intended only as a brief summary of Norbrook products for your convenience. Not all products or indications are licensed in every country and may be subject to further local variations. For specific product information you should always consult a healthcare professional from your region. Please see our terms and conditions for further information.
Contact Us
Further Product Information

Summary of Product Characteristics